Offchain Labs raises $120 million to fix Ethereums shortcomings with its Arbitrum product – TechCrunch

As the broader crypto world enjoys a late summer surge in enthusiasm, more and more blockchain developers who have taken the plunge are bumping into the blaring scaling issues faced by decentralized apps on the Ethereum blockchain. The network has seen its popularity explode in the past year, but its transaction volume has stayed frustratingly stable as the network continues to operate near its limits, leading to slower transaction speeds and hefty fees on the crowded chain.

Ethereums core developers have been planning significant upgrades to the blockchain to rectify these issues, but even in the crypto worlds early stages, transitioning the network is a daunting, lengthy task. Thats why developers are looking to so-called Layer 2 rollup scaling solutions, which sit on top of the Ethereum network and handle transactions separately in a cheaper, faster way, while still recording the transactions to the Ethereum blockchain, albeit in batches.

The Layer 2 landscape is early, but crucial to the continued scalability of Ethereum. As a result, theres been quite a bit of passionate chatter among blockchain developers regarding the early players in the space. Offchain Labs has been developing one particularly hyped rollup network called Arbitrum One, which has built up notable support and momentum since it beta-launched to developers in May, with about 350 teams signing up for access, the company says.

Theyve attracted some high-profile partnerships, including Uniswap and Chainlink, which have promised early support for the solution. The company has also quickly piqued investor interest. The startup tells TechCrunch it raised a $20 million Series A in April of this year, quickly followed up by a $100 million Series B led by Lightspeed Venture Partners, which closed this month and valued the company at $1.2 billion. Other new investors include Polychain Capital, Ribbit Capital, Redpoint Ventures, Pantera Capital, Alameda Research and Mark Cuban.

Offchain Labs co-founders Felten, Goldfeder and Kalodner. Image Credits: Offchain Labs

Its been a fairly lengthy ride for the Arbitrum technology to public access. The tech was first developed at Princeton you can find a YouTube video where the tech is first discussed in earnest back in early 2015. Longtime professor Ed Felten and his co-founders CEO Steven Goldfeder and CTO Harry Kalodner detailed a deeper underlying vision in a 2018 research paper before licensing the tech from Princeton and building out the company. Felten previously served as the deputy U.S. chief technology officer in the Obama White House, and alongside Goldfeder authored a top textbook on cryptocurrencies.

After a lengthy period under wraps and a few months of limited access, the startup is ready to publicly launch the Arbitrum One mainnet, they tell TechCrunch.

This teams scaling solution has few direct competitors a16z-backed Optimism is its most notable rival but Arbitrums biggest advantage is likely the smooth compatibility it boasts with decentralized applications designed to run on Ethereum, compared with competitors that may require more heavy-lifting on the developers part to be fully compatible with their rollup solution. That selling point could be a big one as Arbitrum looks to court support across the Ethereum network and crypto exchanges for its product, though most Ethereum developers are well aware of whats at stake broadly.

Theres just so much more demand than there is supply on Ethereum, Goldfeder tells TechCrunch. Rollups give you the security derived from Ethereum but a much better experience in terms of costs.

Read more:

Offchain Labs raises $120 million to fix Ethereums shortcomings with its Arbitrum product - TechCrunch

Twitter May Soon Let Users Add Bitcoin, Ethereum Addresses to Their Profiles for Tips – Gadgets 360

Twitter is found to be working on allowing users to add Bitcoin and Ethereum addresses to their profiles to receive tips in cryptocurrencies. The new addition could be aimed to upgrade the Tip Jar feature that the microblogging network introduced earlier this year. Twitter is working on the ability to let users receive tips in Bitcoin through the Tip Jar feature. CEO Jack Dorsey in July suggested the implementation by calling Bitcoin a big part of the company's future in conversation with analysts and investors.

Mobile app developer Alessandro Paluzzi has found references about Twitter bringing the ability to let users add Bitcoin and Ethereum addresses to their profiles. The developer posted a tweet that carried three screenshots to indicate the new options.

The first screenshot suggests that users would be able to copy Bitcoin and Ethereum addresses to send tips in any of the two cryptocurrencies using the Tip Jar feature. In the second and third ones, Twitter appears to allow users to add Bitcoin and Ethereum addresses to their profiles.

Alongside the screenshots suggesting the addition of Bitcoin and Ethereum address options, Paluzzi on Wednesday tweeted a screenshot to suggest the arrival of Bitcoin support to the Tip Jar feature. That tweet received a comment from Twitter's product lead Kayvon Beykpour that includes a lightning bolt emoji along with another saying soon to confirm its development and its imminent release.

Beykpour did not provide any further details about when exactly the ability to receive tips in Bitcoin through Tip Jar will be available to users. However, the screenshot posted by Paluzzi does suggest that Twitter would consider payment transfer technology The Lightning Network to allow tipping in Bitcoin on its platform.

The screenshot also suggested that Twitter would use Strike to generate Bitcoin Lightning invoices for the cryptocurrency tips users will get through the platform. Paluzzi on his newer tweet, though, says that users will not be required to link a Strike account for adding their Bitcoin and Ethereum addresses.

A report by MacRumor says that the work for Bitcoin tips has been suggested through Twitter for iOS beta code. It isn't available to beta testers at this moment, though.

In May, Twitter introduced its Tip Jar feature to let creators, journalists, and nonprofits monetise their tweets in the form of tips. The company initially enabled users to share links to their Bandcamp, Cash App, Patreon, Paypal, and Venmo accounts for receiving tips from their followers. That was, however, just the beginning as the platform appears to be adding cryptocurrencies as the new payment options.

Twitter CEO Jack Dorsey has advocated cryptocurrencies for some time. In August, he said that Bitcoin would unite a deeply divided country. Dorsey during Twitter's earnings call in July also called the big part of Twitter's future.

I think there's a lot of innovation above just currency to be had, especially as we think about decentralising social media more and providing more economic incentive, he said while answering a question on how he sees Bitcoin becoming an integral part of Twitter.

See more here:

Twitter May Soon Let Users Add Bitcoin, Ethereum Addresses to Their Profiles for Tips - Gadgets 360

Nvidia’s CMP170HX in the Wild With 164 MHps of Ethereum Mining Performance – Tom’s Hardware

Reports on Nvidia aiming to repurpose its A100 compute accelerator as a Crypto Mining Processor accelerator surfaced as early as March of this year. The intermediate radio silence has now been broken, with purported photographs and screenshots of a repurposed A100 surfacing as a rebranded CMP 170HX. There's plenty to chew over, but as this isn't an officially announced product, take the details with a bit of salt.

While initial reports pointed towards a CMP 220HX branding with performance in the range of 215 MH/s for Ethereum mining, the final result delivered by the CMP 170HX is slightly less impressive, with the tested card delivering around 165 MH/s in a 250W envelope. It is still extremely impressive compared to the CMP 50HX accelerator that falls in the same 250 W envelope, though; that card can only output 45 MH/s less than a third of the CMP 170HX's performance. Thus, Nvidia seems to still have some headroom for an eventual 220HX release - at least judging from these specifications on offer in the 170HX.

The CMP 170HX is likely made via defective, harvested chips that didn't make it into the company's A100 - a beast of a card with 40 or 80 GB of HBM2e memory and packing a grand total of 6,980 enabled CUDA cores (84% of the in-silicon CUDA cores in the GA100 chip design).

Being a cryptocurrency mining-oriented card, Nvidia cut everything that wasn't strictly necessary for typical mining workloads. Besides the aforementioned headless design, the CMP170HX features only 4,480 CUDA cores (54% of GA100's design cores). Its HBM2e memory has been reduced to the bare minimum for Ethereum mining, with 8 GB HMB2e across two 4 GB stacks, delivering a maximum of 1,493 GB/s of bandwidth across its 4096-bit bus. Nvidia even slaughtered the PCIe bus on this card - the link is limited to PCIe 1.1 x4 (!), thus offering only 250 MB/s bandwidth across the PCIe bus (for reference, modern graphics cards with PCIe 4.0 x16 achieve 32 GB/s across the bus). However, mining workloads aren't dependant on the bus speed for performance - while most other applications users might want to use these cards for (like, say, actual ML and typical HPC workloads) will thus be rendered virtually impossible to process at a high enough throughput to make it worthwhile.

These alterations allow Nvidia to sell this card solely for cryptocurrency mining, at a premium, while keeping institutions, data centers and even tech-savy prosumers focused on the company's A-series offerings, also at a premium.

GPU-Z screenshots of the card, which has "170hx" added to cover whatever name has been assigned to the card in the identifier string, identify it with the 20C2 Device ID. The card was running on Nvidia's 471.41 driver version and core clocks are set at an 1140 MHz base and 1410 MHz boost. This is likely in the sweet spot for performance and power consumption for this particular accelerator since memory speeds, not core speeds, are the defining factor in cryptocurrency mining performance. This also enables a fully passive design since in-memory processing is less heat-intensive than in-core processing.

CMP is Nvidia's crypto-specific accelerator lineup, built to take some of the strain off the company's gaming-oriented GeForce lineup by streamlining the cards' design and extracting the bits and pieces that aren't required for crypto mining operations, such as the display outputs. All of Nvidia's CMP lineup, including the CMP 30HX, 40HX, 50HX and 90HX (with relative performance scaling with the product numerals), are headless.

Now there's one more tool to attract miners towards these graphics cards instead of our general GeForce graphics cards. Even with Nvidia's Lite Hash Rate performance limitation, these cards still present interesting venues for mining income. However, don't expect these CMP 170HX to be scooped up in droves by mainstream miners: While its pricing isn't currently known, the GA100 die inside is expensive for Nvidia to produce. However, it will definitely be an appealing solution to larger-scale mining operations it does qualify as one of the most efficient and higher-performing mining solutions in a single card currently available in the market.

Continue reading here:

Nvidia's CMP170HX in the Wild With 164 MHps of Ethereum Mining Performance - Tom's Hardware

New Ethereum-based NFT Project From Artist Behind The Bored Ape Yacht Club – Benzinga – Benzinga

A highly anticipated NFT project will become available to the public in the coming weeks on the Ethereum (CRYPTO: ETH) platformfrom one of the artists behind the Bored Ape Yacht Club.

What Happened: The digital artist known as Migwashere is launching a new NFT club called the Sneaky Vampire Syndicate. The project will mint 8,888 NFTs over the coming weeks, according to Decrypt.

The Vampire NFTs feature cartoon portraits, distributed as tokens using the Non-Fungible Token Standard (ERC-721) on the Ethereum blockchain. They will be available at a cost of 0.08 ETH each, or approximately $313 apiece.

The projects Discord server has already drawn over 12,000 followers since Tuesday.

Related Link:Sotheby's Set To Auction 101 Bored Ape Yacht Club NFTs: What You Should Know

Whats Next: Migwashere says the Sneaky Vampire Syndicate is under his full control, unlike The Bored Ape Yacht Club, which involved a team of artists. This one feels more like something Ive created, he tells Decrypt.

There are plans to also release a 2D fighting video game featuringthe vampire NFTs. Developers say only NFT owners would be allowed to play the game.

Prior to launching the project, 400 people will be selected for a pre-sale, which will give them a chance to mintup to two vampire NFTs. To qualify you must engage with the project on Discord or Twitter.

Related Link:Logan Paul, Chris Camillo Buy Bored Ape Yacht Club NFTs, Floor Rises: What Investors Should Know

Photo: Courtesy of@migwashere2twitter account

Originally posted here:

New Ethereum-based NFT Project From Artist Behind The Bored Ape Yacht Club - Benzinga - Benzinga

"Ethereum will be Bigger than AWS, Azure and Google combined" – Pekka Kelkka – hackernoon.com

Bitcoin and Ether hit their best values in more than nearly two months, despite concerns surrounding crypto restrictions in the US. YeFi.one founder Pekka Kelkka: We are on the second wave of this bull run and we will hit ATHs quite soon. We must increase regulators and lawmakers understanding of blockchain and cryptos. Im positive that we will find a common ground. The biggest problem is the US politicians who are funded by the US banks and financial institutions. They will fight back but they will give up. Common sense will win.T

Crypto Veteran. Tokenization, DeFi and Security Tokens - Blockchain.

Ishan Pandey: Hi Pekka, welcome to our series Behind the Startup. Please tell us about yourself and the story behind YeFi?

Pekka Kelkka: Officially, the project came to life in mid-March 2021. However, several years before the actual launch of the YeFi.one platform, a team of blockchain entrepreneurs, the future founders, had been living the DeFi revolution, learning its valuable lessons and nurturing an idea of creating a project that would one day combine all the essential decentralized finance functions while eliminating its shortfalls and mistakes of the past.

The founders had also recognized the value of decentralized data storage and computing projects like Filecoin, Swarm, Chia, and Dfinity. That is how the idea to collaborate and promote these projects have emerged.

Ishan Pandey: The Securities and Exchange Commission of the United States has filed its first complaint related to the expanding decentralized finance sector, charging that a corporation traded digital tokens that ought to have been registered with the Wall Street regulator. From a regulatory standpoint, what measures should be introduced so as to induce a better system wherein full and honest disclosure is mandated and practiced?

Pekka Kelkka: We have the best crypto lawyers following closely whats happening not just in the USA cryptos regulatory scene but globally. Unfortunately, at this stage, we do not welcome US investors on our platform.

The bottom line is that the global blockchain and crypto community needs to collaborate with the regulators. We must increase regulators and lawmakers understanding of blockchain and cryptos. Im positive that we will find a common ground.

Blockchain and cryptos will be the biggest change in the global financial and monetary system in centuries and Defi will lead the way. Also, governments and central banks will benefit from the fastest, most cost-efficient, and secure decentralized financial services.

As we know commercial banks are already in the game. A big Switzerland bank Sygnum is already offering DeFi services to its investor customers. All the other banks must follow if they want to continue their business.

Ishan Pandey: Elrond recently stated that it has become carbon negative, as the cryptocurrency sector shifts to more environmentally friendly ideas to reduce its carbon footprint. What are your thoughts on the detrimental environmental impact of cryptos and can we gradually shift towards a more eco-friendly system?

Pekka Kelkka: This is a development led by Elrond. I see that the blockchain and crypto industry can lead the way also on th e carbon negative production front. Blockchain and cryptos can become the greenest business sector which others will follow!

Ishan Pandey: After a big Ethereum upgrade, Bitcoin and Ether hit their best values in more than nearly two months, despite concerns surrounding crypto restrictions in the US infrastructure plan. Do you believe this uptrend is here to stay or will we soon hit a low in the crypto market?

Pekka Kelkka: We are on the second wave of this bull run. It will still last months. We will hit ATHs quite soon. The bear market will come. Not 70-90% cut this time but less. Still, these are my personal opinions. No financial advice.

Ishan Pandey: Biden's huge bipartisan infrastructure project struck a rare chord of bipartisan collaboration between Republicans and Democrats, but the bill is being held up due to proposed changes to cryptocurrency regulation in the US. What does the future look like for cryptocurrencies in the United States?

Pekka Kelkka: Should we be worried? In the end, I believe that US lawmakers will understand that blockchain and cryptos will lead the technology development in the world, just as the internet has done since early 2000. The biggest problem is the US politicians who are funded by the US banks and financial institutions. They will fight back but they will give up. Common sense will win also in the USA.

Ishan Pandey: The biggest significant enhancement to the Ethereum blockchain since 2015, according to Ethereum developer Vitalik Buterin, came into force just recently, and the network is well-positioned to make an even bigger improvement to reduce its energy usage by 99 percent. Can you elaborate on this new improvement and what its implications are for the Ethereum ecosystem?

Pekka Kelkka: How many hours do we have? 🙂

Let me start first by saying this:

Ethereum will be the biggest game-changer in the global business. It will be the global computer. It will be bigger than AWS, Azure, and Google combined.

Ethereum's biggest change on the recent EIP (Ethereum Improvement Proposal) 1559 was the change on the economical model which will make ETH deflationary in the longer run.

Since EIP1559 the base fee amount of ETH is "burned" on every transaction i.e. on every transaction some ETH tokens will be removed from the market circulation.

When transactions on Ethereum will explode - as expected - more ETH will be "burned" than produced (mined). Demand for ETH will become much higher than supply.

What do you think will happen to the ETH price?

But "the money-making machine" of ETH is just a side product. Most importantly Ethereum will become the world computer as I mentioned earlier.

Even more remarkable changes will occur when ETH2.0 will be launched possibly before the end of the year. The major feature of ETH 2.0. Will be Sharding. The Ethereum network will be used much more economically which will reduce the price of the transactions as well as speed up them dramatically.

This will also reduce the energy usage a lot on the Ethereum network.

Ishan Pandey: What new trends are we going to witness within the crypto ecosystem especially in the post-covid-19 era?

Pekka Kelkka: The whole blockchain and crypto scene will explode - watch out mainstream, here we come!

Disclaimer: The purpose of this article is to remove informational asymmetry existing today in our digital markets by performing due diligence by asking the right questions and equipping readers with better opinions to make informed decisions. The material does not constitute any investment, financial, or legal advice. Please do your research before investing in any digital assets or tokens, etc. The writer does not have any vested interest in the company. Ishan Pandey.

Related Stories

Create your free account to unlock your custom reading experience.

Follow this link:

"Ethereum will be Bigger than AWS, Azure and Google combined" - Pekka Kelkka - hackernoon.com

If You Had $5,000 Right Now, Would You Put It On Ethereum Or Baby Dogecoin? – Benzinga

Every week, Benzinga conducts a survey to collect sentiment on what traders are most excited about, interested in or thinking about as they manage and build their personal portfolios.

This week we posed the following question to over 1,000 Benzinga visitors on cryptocurrency investing:

If you had $5,000 to invest, would you put it on Ethereum (CRYPTO: ETH) or Baby Dogecoin (CRYPTO: BABYDOGE) right now?

See Also: How To Buy Baby Dogecoin

Ethereum was trading around $3,900 at press time. Ethereum is trading sharply higher over the past month by 45.7% from the $2,700 price level on July 29th.

Meanwhile, Baby Dogecoin is trading around $0.000000000706.

Baby Dogecoin is a cryptocurrency on the Binance Smart Chain. The project has gained popularity for its cuteness instead of underlying technology Read More

This survey was conducted by Benzinga in August 2021 and included the responses of a diverse population of adults 18 or older.

Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from over 1,000 adults.

2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read more:

If You Had $5,000 Right Now, Would You Put It On Ethereum Or Baby Dogecoin? - Benzinga

Ethereum’s Breach of $4000 Marks Presence Of Whales | investing.com – Investing.com

appeared to be leading the top cryptocurrencies by market cap when it broke past $4,000.

Ethereum was making headlines again, after surging by more than 18% within the past four days to test the psychological $4,000 level.

The second-largest cryptocurrency by market cap its uptrend after consolidating for more than three weeks.

Ether made a series of higher lows throughout the stagnation period, while the $3,350 level prevented it from advancing further. Such market behavior led to the formation of an ascending triangle on ETHs daily chart.

A sudden spike in buying pressure allowed Ethereum to break out of its consolidation pattern on Aug. 31, and rise by more than 18% over the past few days to reach a target of $4,000.

The Fibonacci retracement indicator, measured from the May 12 high of $4,372 to the June 22 low of $1,700, suggests that further buying pressure has more room to push the asset up. Further buying at around the current price levels could see ETH retest its all-time high.

The presence of whales and institutional players on the network suggests Ethereum could even target $5,000 if buying orders continue piling up.

The number of large Ether transactions with a value of $100,000 or greater continues to rise. Roughly 13,770 large transactions were recorded on Sept. 1, and this on-chain metric appears to be trending higher.

Since whales disproportionately impact prices because of their enormous holdings, they can coordinate buying and selling activity to pump or dump tokens. Such is the case that over the past few years, each time the number of large Ether transactions starts to increase, prices tend to follow.

As long as Ethereum can keep its momentum and prices hold above $3,800, further gains can be expected.

Original Post

More here:

Ethereum's Breach of $4000 Marks Presence Of Whales | investing.com - Investing.com

Cell Therapy Manufacturing Market | Exclusive Report on the Latest Market Trends and Development – PharmiWeb.com

Coherent Market Insights has announced new analysis on Cell Therapy Manufacturing Market Status 2021-2027 which has been prepared based on an in-depth market analysis with inputs from industry experts and top vendors in the business. The report covers the market landscape and its development prospects over the coming years. The report also contains a discussion of the key vendors operating in this market.

Request Here For PDF Brochure

Cell therapy is a very effective medicinal procedure, where human cells are injected for restoration of damaged tissue. Cell theory repairs the damaged tissues of an organ rather than producing new organ. With the use new technologies and innovation, cell therapies have gained significant traction and are recognised for potentially treating the wide range of diseases such as immune deficiency, tissue degradation and metabolic disorders. The therapy is classified into two different types. The first one is allogeneic that is cells from third party donor and the second one autologous that is cells from ones own body. The main objective of cell therapy implication is to restore the damaged cells of an organ and allow the similar functioning of damaged tissues as earlier.

Some of the clinical trials of cell therapies were established and permitted. For instance, in 2013, a stage 2 clinical trial for bone marrow transplantation was performed by rheumatoid arthritis deriving stem cells in affected knee. This technique was grown due to collaboration of the government agencies. According to the U.K. 2014 report, government funded US$15.3 million in cell therapy manufacturing market.

Market Drivers:-

The increase in number of chronic diseases would lead to growth of the cell therapy manufacturing market as many such diseases are getting treated by cell therapy. New medications are implanted and regenerative medicine is also highly adopted leading to market growth. Stem cells transplantation is one of the effective medical therapy that treats certain advance stage diseases like diabetes, cancer, arthritis, blindness, cerebral palsy, Alzheimers, autism, etc. For instance, in 2015, World Health Organization (WHO) reported the annual worldwide stem cell transplants reach up to more than 50,000 transplants in various surgeries. The new medical therapy is demanded due to increasing number of trauma and accidents leading to increasing number of surgical procedures across the world. Some of the major biopharmaceutical companies are invested in research for cell therapy. For instance, in 2018, a biopharmaceutical company named as Longeveron LL, received a grant of US$ 750,000 for stem cell therapy research from the Maryland Technology Development Corporation (TEDCO). These government funding and collaborations among companies boosts the cell therapy manufacturing market growth.

Market Opportunities:-

The adoption of cell therapy is increasing in the developing countries. As cell therapy is one of the effective methods to treat certain chronic diseases even at the advanced stage, various developing regions are adopting the method of cell therapy. This gives various opportunities for players in the cell therapy manufacturing market.

Market Restraints:-

The key factor that is declining growth of the cell therapy manufacturing market is high manufacturing cost of cell therapy. As it is not cost effective, patients tends to move towards another option restraining market growth. Moreover, the strict guidelines and regulations, as well as diverse health safety concerns over cell therapy treatment are declining the cell therapy manufacturing market growth.

Regional Analysis:-

The global cell therapy manufacturing market is segmented into North America, Latin America, Asia Pacific, Europe, Africa and Middle East. Among everyone, North America owes largest number of performed surgeries and holds the dominant position in the global cell therapy manufacturing market. North America is also developed in technologically advanced products for therapy. The Centres for Disease Control & Prevention (CDC) provided the National Health Statistics Report that states, US performed around 201,748.3 million non-surgical and surgical procedures in 2011.

Moreover, Asia Pacific is also expected to have a significant growth in the global cell therapy manufacturing market in the near future. Local players in the market would grab marginal market share due to growing patients of various chronic and infectious diseases such as cancer, HIV, hepatitis etc. and less stringent regulatory requirements. Therefore, cell therapy could be at the marginal low cost that would provide better solutions to the patients.

Key Players:-

The key players operating the global cell therapy manufacturing market are Gene Therapy Catapult EUFETS, Pharmicell, CELLforCURE Merck Group, MaSTherCell, Thermo Fisher, Dickinson and Company, Miltenyi Biotec GmBH, MEDIPOST, Cognate BioServices, PharmaCell, Lonza Group, STEMCELL Technologies, Holostem Terapie Avanazate, Bio-Rad Laboratories, Inc., Takara Bio Group, Pluristem Therapeutics, Cellular Dynamics International, Anterogen, Becton, Brammer Bio, Osiris Therapeutics, and WuXi AppTec.

Some of the key players are adopting growth strategies such as introduction of new technologies and devices to keep up the top position in the market. For instance, for treating type 1 diabetes ViaCyte, Inc. successfully implanted VC-01 an embryonic stem cell derived islet in 2014.

Buy instant copy of this research report with Flat US $ 2000 Off@ https://www.coherentmarketinsights.com/promo/buynow/1728

Main points in Cell Therapy Manufacturing Market Report Table of Content

Chapter 1 Industry Overview1.1 Definition1.2 Assumptions1.3 Research Scope1.4 Market Analysis by Regions1.5 Cell Therapy Manufacturing Market Size Analysis from 2021 to 202711.6 COVID-19 Outbreak: Cell Therapy Manufacturing Industry Impact

Chapter 2 Global Cell Therapy Manufacturing Competition by Types, Applications, and Top Regions and Countries2.1 Global Cell Therapy Manufacturing (Volume and Value) by Type2.3 Global Cell Therapy Manufacturing (Volume and Value) by Regions

Chapter 3 Production Market Analysis3.1 Global Production Market Analysis3.2 Regional Production Market Analysis

Chapter 4 Global Cell Therapy Manufacturing Sales, Consumption, Export, Import by Regions (2016-2021)Chapter 5 North America Cell Therapy Manufacturing Market AnalysisChapter 6 East Asia Cell Therapy Manufacturing Market AnalysisChapter 7 Europe Cell Therapy Manufacturing Market AnalysisChapter 8 South Asia Cell Therapy Manufacturing Market AnalysisChapter 9 Southeast Asia Cell Therapy Manufacturing Market AnalysisChapter 10 Middle East Cell Therapy Manufacturing Market AnalysisChapter 11 Africa Cell Therapy Manufacturing Market AnalysisChapter 12 Oceania Cell Therapy Manufacturing Market AnalysisChapter 13 South America Cell Therapy Manufacturing Market AnalysisChapter 14 Company Profiles and Key Figures in Cell Therapy Manufacturing BusinessChapter 15 Global Cell Therapy Manufacturing Market Forecast (2021-2027)Chapter 16 ConclusionsResearch Methodology

Request for a Sample Report

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Phone: US +12067016702 / UK +4402081334027Email: sales@coherentmarketinsights.com

View original post here:

Cell Therapy Manufacturing Market | Exclusive Report on the Latest Market Trends and Development - PharmiWeb.com

MD Anderson Now to Offer Solution for Cellular Therapy Toxicities – Targeted Oncology

CaspaCIDe safety switchcontains a CID-binding domain which is connected to the signaling domain of caspase-9. With an infusion of rimiducid, the caspase-9 domain is activated, causing selective apoptosis of the CaspaCIDe-containing cells. The purpose of this technology to help with the common adverse events (AEs) observed with the use of cellular therapies in patients with cancer, such as cytokine release syndrome (CRS) and neurotoxicity. The technology can also be administered long after the initiation of a cellular therapy.

The unique inducible caspase-9 technology covered by this agreement has the potential to reduce the risk of serious adverse events associated with cellular therapies and to improve patient outcomes, saidKaty Rezvani, MD, PhD, professor ofStem Cell Transplantation and Cellular TherapyatMD Anderson, in a press release. We have successfully applied the technology to existing cell therapies, and we look forward to the potential future applications made possible by this agreement.

Research shows that adoptive cell therapies (ACTs) lead to AEs that are more prevalent than AEs associated with radiation and chemotherapy, and the AEs from cellular therapies can last for several years. CRS, the most common toxicity, is observed with all ACTs and typically manifests as fever and chills to start. Immunosuppressive agents like glucocorticoids and anti-IL-6/IL-6 receptor antibodies are used to treat CRS, however experts still consider this AE to be a challenge in patients with cancer.2

The use of chimeric antigen receptor (CAR) T-cell therapies, T-cell receptor engineering therapies (TCR-T) and tumor-infiltrating lymphocyte (TIL) therapy can cause neurotoxicity, which has clinical characteristics like confusion, delirium, expressive aphasia, obtundation, myoclonus, and seizure. This toxicity can be concurrent with CRS, making for a bigger treatment challenge. Other AEs related to the use of cellular therapies include off-target associated with both CAR T-cell therapy, and high dose IL-2related toxicity associated with TILs.

In studies, the CaspaCIDe safety switchhas demonstrated improvement of symptoms within rimiducid 24 hours. There are 45 clinical trials ongoing at MD Anderson that may be impacted by this license agreement. Currently, MD Anderson is the site for 12 clinical trials of chimeric antigen receptor T-cell therapies, 5 trials of T-cell receptor engineering therapies, 5 studies of tumor-infiltrating lymphocytes, and 23 trial of natural killer cell therapies.1

We are excited to expand our CaspaCIDe agreement with MD Anderson to include a broader set of programs to benefit cancer patients, said Rick Fair, president and CEO of Bellicum Pharmaceuticals, in the press release. We believe that our switch technology may enhance the benefit/risk profile of cell therapies. We intend to continue to pursue opportunities to expand its use via external collaborations with other leaders in the field.

Reference:

1. MD Anderson and Bellicum announce additional license agreement for use of CaspaCIDe safety switch. News release. MD Anderson Cancer Center. September 1, 2021. Accessed September 3, 2021. https://bit.ly/38AgSHs

2. Jin Y, Dong Y, Zhang J, et al. The toxicity of cell therapy: Mechanism, manifestations, and challenges. J Appl Toxicol.2021;41(5):659-667. doi: 10.1002/jat.4100

Here is the original post:

MD Anderson Now to Offer Solution for Cellular Therapy Toxicities - Targeted Oncology

Dr. Van Rhee on Future Research Directions for CAR T-Cell Therapy in Multiple Myeloma – OncLive

Frits van Rhee, MD, PhD, discusses future research directions with CAR T-cell therapy for the treatment of patients with multiple myeloma.

Frits van Rhee, MD, PhD, professor and director of the myeloma center at the University of Arkansas for Medical Sciences, and Charles and Clydene Scharlau Chair for Hematological Malignancies, discusses future research directions with CAR T-cell therapy for the treatment of patients with multiple myeloma.

A significant question that remains with CAR T-cell therapy in for patients with multiple myeloma is where it fits into the treatment algorithm, according to van Rhee. It is feasible that this therapy could be given early in the course of treatment, such as for patients who experience early relapse, those who are diagnosed with aggressive disease, or as a replacement for stem cell transplantation, van Rhee says.

Another future opportunity with this modality is to improve upon existing CAR T-cell therapies, van Rhee adds. Thus far, CAR T-cell therapy has been exciting due to the results obtained with only first-generation products, van Rhee notes. To build on this, it is important to examine how to make these treatments persist, and last longer in patients, as well as understand how the bone marrow microenvironment affects the efficacy of these treatments, van Rhee concludes.

Read more here:

Dr. Van Rhee on Future Research Directions for CAR T-Cell Therapy in Multiple Myeloma - OncLive

BioRestorative Therapies Receives Patent in Japan Related to its Off-the-Shelf ThermoStem Program – GuruFocus.com

Patent Issued Grants Protection for Deriving Brown Adipocytes from Brown Adipose (Fat)-Derived Stem Cells

MELVILLE, N.Y., Aug. 31, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the Company) ( BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Japanese Patent Office has issued the Company a patent related to its metabolic ThermoStem Program.

Claims granted under the new patent cover methodologies related to brown adipocytes from human brown adipose (fat)-derived stem cells. Brown adipocytes are a type of fat tissue found in humans that regulate metabolic activity. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

We are pleased to see that we have been granted a significant patent by the Japanese Patent Office for our ThermoStem Program, said Lance Alstodt, the Companys CEO. The value of our intellectual property assets under our ThermoStem Program continues to grow as we are gaining additional international protection.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

Disc/Spine Program (brtxDISC): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a persons own) cultured mesenchymal stem cells collected from the patients bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patients bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patients damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.

Metabolic Program (ThermoStem): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:Email: [emailprotected]

See more here:

BioRestorative Therapies Receives Patent in Japan Related to its Off-the-Shelf ThermoStem Program - GuruFocus.com

NCCN Issues Updated Guidelines Regarding Third COVID-19 Vaccine Booster for Those With Cancer – Cancer Network

The National Comprehensive Cancer Network (NCCN) has announced a significant update to the guidelines for COVID-19 vaccine administration, including a third dose, in patients with cancer, according to a press release issued by the organization.1

The recommendation indicated that several groups of individuals should be eligible for a third dose of the COVID-19 vaccine, including those with new or recurring solid tumors within 1 year of their initial vaccine dose regardless of therapy, as well as those with active hematologic malignancies. Patients who have received a stem cell transplant (SCT) or engineered cellular therapy such as CAR T-cell therapy within the past 2 years should also eligible, as well as those who are recipients of SCT on immunosuppressive therapy or with a history of graft-versus-host disease regardless of when the transplant took place.

COVID-19 can be very dangerous, especially for people living with cancer, which is why were so grateful for safe and effective vaccines that are saving lives, Robert W. Carlson, MD, chief executive officer of the NCCN, said in a press release. Our organization exists to improve the lives of people with cancer; we have a long track record for making recommendations that improve quality and length of life. We want our patients to live the longest and best lives possible, which means following the science on vaccination and mask-wearing.

The NCCN COVID-19 Vaccine Advisory Committee consists of multidisciplinary physicians across the NCCNs Member Institutions. In particular, the committee includes experts in infectious diseases, vaccine development and delivery, cancer management, and medical ethics. The recommendations, which are based on available evidence and expert consensus, have been utilized globally to aid in making management decisions over the course of the COVID-19 pandemic.

When it comes to peoples safety, we have to take every precaution, Steve Pergam, MD,

MPH, associate professor of the Vaccine and Infectious Disease Division at Fred Hutchinson

Cancer Research Center and infection prevention director at Seattle Cancer Care Alliance, as well as the co-leader of the NCCN COVID-19 Vaccination Advisory Committee, said in a press release. That means even after a third dose of vaccine, we still recommend immunocompromised peoplesuch as those undergoing cancer treatmentcontinue to be cautious, wear masks, and avoid large group gatherings, particularly around those who are unvaccinated. All of us should do our part to reduce the spread of COVID-19 and get vaccinated to protect those around us from preventable suffering.

Additional recommendations from the updated guidelines suggest that all eligible caregivers and close contacts of those with cancer should be immunized whenever possible.2 The use of all vaccines with FDA approval or emergency use authorizationincluding the Pfizer/BioNTech BNT162b2 mRNA vaccine (Comirnaty), the Moderna mRNA-1273 SARS-CoV-2 vaccine, and the Janssen Ad26.COV2.S Adenovirus vector vaccineis recommended in eligible patients by the committee.

Those who are receiving allogeneic or autologous SCT or CAR T-cell therapy will need to wait at least 3 months post-therapy before receiving the vaccine. Patients with hematologic malignancies, including those receiving cytotoxic chemotherapy such as cytarabine and anthracycline-based induction regimens for acute myeloid leukemia, need to delay inoculation until absolute neutrophil count recovery. Those who are experiencing marrow failure from their disease and/or are expected to have limited or no recovery from their therapy as well as those who are receiving long-term maintenance are able to receive the vaccine once it is available.

In solid tumors, the vaccine may be received once available for those who are undergoing treatment with cytotoxic chemotherapy, targeted therapy, checkpoint inhibitors, and other immunotherapy or radiation therapy. Those who are undergoing major surgery need to wait a few days following their surgical procedure before getting the vaccines.

The Center for Disease Control (CDC) currently recommends a third dose of the mRNA COVID-19 vaccines for individuals who are moderately to severely immunocompromised. This includes:

The CDC recommends that a third dose of the mRNA COVID-19 vaccine should be given at a minimum of 4 weeks following the second dose of either the Moderna or Pfizer vaccines. Notably, although preliminary data indicate that a third dose could augment antibody titers in an immunocompromised population of patients, those who have been diagnosed with cancer continue to be at a higher risk for infection with COVID-19 and COVID-19related complications. Even with the additional dose, infection is still possible meaning that precautions such as avoiding crowds and wearing a mask are recommended.

Read the original here:

NCCN Issues Updated Guidelines Regarding Third COVID-19 Vaccine Booster for Those With Cancer - Cancer Network

Jury awards North Texas doctor $7.8 million in lawsuit over his partner locking him out – The Dallas Morning News

A jury awarded a North Texas physician $7.8 million after finding his business partner locked him out of their jointly owned stem cell therapy clinic in 2018.

Wade McKenna, an orthopedic surgeon and CEO of McKenna Orthopedics and Biologics, sued his former partner Neil Riordan for conspiring to ax him from his ownership stake in the Southlake-based Riordan-McKenna Institute and transfer the companys assets to another clinic Riordan owned.

Riordan, a scientist specializing in stem-cell research, ran the Riordan Medical Institute at the same location as the Riordan-McKenna Institute following the schism, using the same initials as the original clinic.

Jurors in a Tarrant County District Court found that McKenna wasnt fairly compensated for the assets transferred to the Riordan Medical Institute or for the revenue generated at the competing business.

You see business splits quite a bit, but usually not something this egregious, said Derrick Boyd, McKennas lead trial lawyer from Boyd Powers & Williamson.

Riordan said he was disappointed in the decision and would be pursuing post-trial options.

We disagree mightily with the result in the trial and plan to present appropriate post-trial motions to the court and, if necessary, to appeal this unjust ruling result to the court of appeals, Riordan said.

McKennas dismissal from the Riordan-McKenna Institute caught the doctor off guard, Boyd said. On May 16, 2018, Riordans lawyer delivered McKenna a letter stating that Riordan wished to sever their business partnership.

The current board, which consists of Dr. Riordan and David Murfin, has determined that it is in the best interest of RMI to terminate your affiliation with RMI in all regards including, but not limited to, your role as medical director, the letter said. As such, Dr. Riordan requests that you turn in your keys to the RMI office.

The letter gave two options for the future of the company: a dissolution or a buyout. Under the buyout, Riordan offered to buy McKennas 45% stake in the company for $500,000.

Boyd said McKenna was denied access to company financial records when he questioned the suggested buyout compensation, inspiring McKenna to sue his former partner.

In the lawsuit that was decided Aug. 31, jurors said Riordan failed to comply with his fiduciary duty to the company and that McKenna, as a member of the institute, had a right to assert such a claim.

Under the decision, McKenna was awarded damages for his stake in the company, improper financial distributions to Riordan-owned entities and a 45% share of amounts improperly received by Riordan or Riordan-owned entities from operations at RMI after May 16, 2018.

The verdict also included $5 million in punitive damages, Boyd said.

Go here to read the rest:

Jury awards North Texas doctor $7.8 million in lawsuit over his partner locking him out - The Dallas Morning News

Iomab-B Shows Early Promise Versus Standard Therapy in Elderly R/R AML – Targeted Oncology

The theory is currently being investigated in the phase 3 SIERRA trial (NCT02665065) of the radio immunotherapy Iomab-B versus the standard of care (SOC). Preliminary safety data from the study showed that myeloablative conditioning with Iomab-Bled to lower rates of severe mucositis, febrile neutropenia, and sepsis compared with SOC, even though radiation was administered at a high dose. The early findings suggest that use of myeloablative conditioning with Iomab-Bmay be beneficial to elderly patients with relapsed/refractory AML prior to hematopoietic stem cell transplantation.

One-hundred fifty patients will be enrolled in the study, and preliminary safety results were available for 54. The cohort received a median dose of 636 mCi (range, 354-1027 mCi)of Iomab-B. The median dose of radiation to the marrow in the Iomab-B group was 4.9 Gy (range, 4.6-32 Gy)and to the GI tract was 2.8 Gy to GI tract.

In an interview with Targeted Oncology, Rajneesh Nath, MD, director of Stem Cell Transplant at Banner MD Anderson, discussed the need for novel treatment for elderly patients with relapsed/refractory AML and how the SIERRA trial is designed to help.

TARGETED ONCOLOGY: What are outcomes like for patients who cannot tolerate transplant. What was additionally done to help these patients in your study?

Nath: Acute myeloid leukemia is the disease of the elderly. The median age at diagnosis is about 68 years and it's continuing to increase 1 to 2 years. Traditionally, and in different database, we saw that as the patients get older with the diagnosis of AML, they don't tend to do well with whatever treatment we throw at them. And 1 to 2 years survival is of the order of 10% or less. Traditionally, these patients will get an induction chemotherapy, if they can tolerate it. If they go into complete remission, patients who would be eligible for as allogeneic stem cell transplant. There are a lot of beliefs about the elderly patients, most hematologists in have a set cutoff age for after which they will not refer patients to a transplant, but this is not the case anymore. There's several studies that have shown that older patients who undergo allergenic stem cell transplant are able to do equally as well as some of the younger patients.

What was the hypothesis targeted delivery of Iomab-B to the marrow in patients with relapsed/refractory AML?

Generally speaking, there are 2 kinds of transplant myeloablative and reduced intensity. Myeloablation goes with increased intensity of chemotherapy and higher doses of radiation. What happens is this increase intensity increases toxicity. With targeted Myeloablation, what we are doing is delivering radiation where it is needed, and that is to the bone marrow. So, what we are able to do is target radiation to the sites where there is leukemia, and at the same time, save the critical orders that include heart, lungs, kidneys.

In the particular study, what we show is that while we are able to deliver myeloablative doses of chemotherapy to the bone marrow, we can spare the GI tract, which means that there will be less mucositis and GI toxicity which will translate to a decrease in neutropenic fever and sepsis.

Can you provide an overview of the study?

This was an interim analysis of the SIERRA trial of Iomab-B in elderly relapsed/refractory patients with AML. The way that trial worked was if you are over the age of 55, and have a relapsed or refractory acute myelogenous leukemia, and you have a fully matched donor. These patients are randomized one to one either to the Iomab-B, which is the experimental arm or the standard of care arm. If they go to the Iomab-B, they get a transplant, even though they have an active disease at the time. If they go into remission, we look at what is the duration of remission, and the primary end point of the trial is 6-month duration of remission.

In that case that they are randomized to the standard of care, they can get whatever chemotherapy of the choosing of the treating oncologist, if they go into remission after receiving that chemotherapy, they can get a standard stem cell transplant or the treating physicians oncologist team, or if they do not go into remission, they can be crossed over to the Iomab-B arm. What we looked at was the toxicity in these 2 groups of patients.

What were the result of this study?

Only about 4% of the patients in Iomab-B arm had sepsis. This was in contrast to 13% of the patients who receive standard of care treatment. Also, with Iomab-B, we saw 40% neutropenic fever, which would be expected, and less than 10% of the patients had grade 3 or 4 mucositis.

What is next for this study?

Only 75% of the land enrollment is a complete. We expect to complete the study this year when total of 150 patients will be randomized. And the next million-dollar question is we have shown in several of the interim analyses that the procedure is safer and is not toxic. The next real question is, is this effective as compared to the standard of care treatment? Once the analysis is complete, we'll know the answer to that.

As this treatment strategy moves forward in clinical trial development, what is your vision for its future use in this patient population? Are there any other exciting strategies emerging for the older subgroup?

It's an exciting time to be treating elderly patients with acute myeloid leukemia. Until a couple of years ago, we didn't have anything for them, we would just see which patients would be eligible for induction which many of these patients were not. We recently had several new approvals for this disease.

One of the particular areas that I'm excited about is the use of combination of hypomethylating agents with venetoclax [Venclexta]. This combination is able to free a lot of elderly patients and put them into remission. It serves as a pathway to take them to stem cell transplant because the outcomes of stem cell transplant are better if they are done in remission. So, on one hand, we are able to put an increasing number of patients into remission and provide them a pathway for stem cell transplant. On the other hand, if this study works out, we will be having a pathway for patients who do not go into remission, also to proceed with an allergenic stem cell transplant.

In your opinion, what promise does myeloablative targeted conditioninghave for the future?

This technology, while initially may be approved for acute myeloid leukemia in the elderly, may have role in several other clinical situations, like patients who have comorbidities and are not able to get full intensity chemotherapy. We can also use this technology in patients who go into transplant with minimal residual disease, though these patients may be technically considered in remission. Because they have small amount of disease, they do not do as well as those patients who are transplanted who are in an MRD-negative state. So, it will open up a lot more areas where we can consider using this technology.

Reference:

Nath R, Choe H, Stiff P, et al.Myeloablative Targeted conditioning with anti-cd45 iodine (131I) apamistamab [Iomab-b] spares the GI tract and has low incidence of severe mucositis, febrile neutropenia and sepsis in the prospective, randomized phase 3 SIERRA trial for patients with relapsed or refractory acute myeloid leukemia (AML). Presented at: 2021 Transplantation & Cellular Therapy Meetings; February 8-12, 2021; Virtual. Abstract 59.

The rest is here:

Iomab-B Shows Early Promise Versus Standard Therapy in Elderly R/R AML - Targeted Oncology

Pirtobrutinib Exhibits Promising Efficacy in Heavily Pretreated MCL and Other Non-Hodgkin Lymphomas – OncLive

The highly potent and selective non-covalent BTK inhibitor resulted in an overall response rate (ORR) of 52% (95% CI, 38%-65%) in patients with MCL (n = 56), with a 25% complete response (CR) rate, a 27% partial response (PR) rate, and a stable disease rate of 18%.

Among patients who were pretreated with BTK inhibitors (n = 52), the ORR achieved with pirtobrutinib was the same, at 52% (95% CI, 38%-66%); the CR, PR, and stable disease rates were 25%, 27%, and 17%, respectively. Notably, efficacy with the agent was also observed in those who previously underwent stem cell transplant (n = 9/14) or CAR T-cell therapy (n = 2/2), with rates of 64% and 100%, respectively.

The ORR with pirtobrutinib was higher in those with Waldenstrm macroglobulinemia (n = 19), at 68% (95% CI, 44%-87%), which included a PR rate of 47%, a molecular response (MR) rate of 21%, and a stable disease rate of 16%. BTK pretreated patients with Waldenstrm macroglobulinemia (n = 13) experienced an ORR of 69% (95% CI, 39%-91%), with a PR rate of 39%, a MR rate of 31%, and a stable disease rate of 8%.

The ORRs experienced in patients with Richters transformation (n = 8), follicular lymphoma (n = 8), marginal zone lymphoma (n = 9), and diffuse large B-cell lymphoma (n = 25) were 75% (95% CI, 35%-97%), 50% (95% CI, 16%-84%), 22% (95% CI, 3%-60%), and 24% (95% CI, 9%-45%), respectively.

Pirtobrutinib is well tolerated and exhibits promising efficacy in heavily pretreated patients with MCL and other non-Hodgkin lymphomas, lead study author Alvaro J. Alencar, MD, of Sylvester Comprehensive Cancer Center, and colleagues, wrote. Durable responses in BTK pretreated MCL are particularly notable, given poor outcomes with existing therapeutic options.

In the phase 1/2 BRUIN trial, investigators set out to evaluate the safety and efficacy of pirtobrutinib in previously treated patients with advanced B-cell malignancies. To be eligible for participation, patients needed to be 18 years of age or older, an ECOG performance status of 0 to 2, and active disease in need of treatment.

A total of 323 patients were enrolled to the trial; 203 of these patients were enrolled to the phase 1 escalation and expansion portion of the trial, where they received the agent at a once-daily dose ranging from 25 mg to 300 mg, and 120 patients to the phase 3 portion, where they received a once-daily dose of 200 mg.

Key end points of the trial include safety and tolerability, determining the maximum-tolerated dose (MTD) and recommended phase 2 dose (RP2D), pharmacokinetics, and efficacy with respect to ORR and duration of response based on disease criteria.

The median age of participants was 68.3 years, 69% were male, 50% had an ECOG performance status of 0, and the median number of prior lines of systemic therapy was 3. Previous treatments included BTK inhibitors, chemotherapy, anti-CD20 antibody, BCL-2 inhibitors, PI3K inhibitors, lenalidomide (Revlimid), CAR T-cell therapy, autologous stem cell transplant, and allogeneic stem cell transplant. The majority of patients who discontinued prior BTK inhibitors did so because of disease progression.

Among 323 patients included in the safety population, no dose-limiting toxicities were reported and the MTD had not been reached. The most frequent treatment-emergent adverse effects (TEAEs) experienced by 10% or more of patients included fatigue, diarrhea, and contusion. AEs of special interest included bruising, rash, arthralgia, hemorrhage, hypertension, atrial, and fibrillation/flutter.

Of these patients, 1.5% discontinued treatment because of treatment-related AEs. The RP2D for pirtobrutinib was established as once-daily 200 mg. No notable covalent BTK inhibitorassociated toxicities were rarely reported.

Longer follow-up is needed to better understand the pirtobrutinib safety profile associated with chronic administration, the study authors concluded.

See original here:

Pirtobrutinib Exhibits Promising Efficacy in Heavily Pretreated MCL and Other Non-Hodgkin Lymphomas - OncLive

Hematopoietic Stem Cell Transplantation (HSCT) Market by Sales, Revenue, Price and Gross Margin (2021-2027) UNLV The Rebel Yell – UNLV The Rebel Yell

Hematopoietic somatic cell Transplantation (HSCT) may be a specialized sort of blood somatic cell transplant therapy. The term hematopoietic refers to the function of the stem cells in citizenry . Stem cell refers to specialized somatic cell types which are capable of developing into specific cells like bone, muscle, blood, and nerve cells.

The PDF for the study can be requested using the following link: https://www.coherentmarketinsights.com/insight/request-pdf/1250

Hematopoietic somatic cell transplantation are often utilized in the treatment of certain cancers of the blood or bone marrow, like myeloma or leukemia. High prevalence of such diseases is predicted to assist in growth of the hematopoietic somatic cell transplantation (HSCT) market. consistent with Leukemia and Lymphoma Society, 176,200 people within the US are expected to be diagnosed with leukemia, lymphoma or myeloma in 2019.

The hematopoietic somatic cell transplantation (HSCT) market in North America is witnessing high growth, due to high adoption of allogeneic hematopoietic somatic cell transplant. Around 30,000 patients undergo allogeneic hematopoietic somatic cell transplant annually within the us .

Hematopoietic cell transplantation is that the transplantation of stem cells, generally derived from bone marrow, duct , or peripheral blood. It also can be allogenic, autologous or syngeneic. the foremost common sort of somatic cell transplant is that the allogenic transplant, which is actually the method of harvesting such stem cells that have the power to become many various specialized cell types, like bone, kidney, heart, liver, lungs, pancreas, nervous, and immune cells. However, approximately 20% to 85% of the patients develop acute Graft Versus Host Disease that affects the skin, gut, or liver. Such scenario hinders the expansion of hematopoietic somatic cell transplantation (HSCT) market.

There are different methods of transplant. just in case of a basic transplant, the stem cells are directly transplanted into an individuals veins, while a minimal invasive procedure also referred to as a micro-implantation requires the injection of the cells into the patients veins. supported the precise needs of the patient, the precise sort of transplant is completed . for instance , a toddler who has undergone bone marrow transplantation can continue to possess other somatic cell types utilized for an equivalent purpose. this is often one among the foremost commonly performed sorts of transplants.

High prevalence of red blood cell anemia is additionally expected to assist in growth of the hematopoietic somatic cell transplantation (HSCT) market. Specially created somatic cell therapies are often utilized in the treatment of red blood cell anemia. These cells are basically taken from the bone marrow of the person then induced to make a thick, jelly like substance. The patient will got to take medicine for a couple of days after the procedure to assist his bodily process the cells.

Hematopoietic cell transplantation has its own set of complications, which limit the expansion of the hematopoietic somatic cell transplantation (HSCT) market. a number of these include infection, allergies , bleeding, and scarring. Infection can occur if theres a severe immune deficiency. The patient also will need to take antibiotics to clear up the infections. If the stem cells are used, they need to be grown under very strict conditions to avoid rejection. Most surgeons attempt to perform this transplant first on those people that suffer from serious diseases like leukemia or cancer as these are the people that stand the simplest chance to achieve success .

Competitive Landscape

Key players operating in the Hematopoietic Stem Cell Transplantation (HSCT) Market are Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Talaris Therapeutics, Inc., Marker Therapeutics Inc., and Stempeutics Research Pvt Ltd.

We also offer 15% FREE Report customization.Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/1250

Contact Us

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Phone: US +12067016702 / UK +4402081334027Email: sales@coherentmarketinsights.com

See the article here:

Hematopoietic Stem Cell Transplantation (HSCT) Market by Sales, Revenue, Price and Gross Margin (2021-2027) UNLV The Rebel Yell - UNLV The Rebel Yell

MD Anderson and Bellicum Announce Additional License Agreement for Use of CaspaCIDe Safety Switch – Newswise

Newswise HOUSTON The University of Texas MD Anderson Cancer Center and Bellicum Pharmaceuticals, Inc. today announced a global option and license agreement covering certain intellectual property and technology rights regarding Bellicums CaspaCIDe (inducible caspase-9, or iC9) safety switch and related technologies, and the use of rimiducid, an agent used to activate the safety switch. Under this agreement, MD Anderson will have the option to incorporate CaspaCIDe into certain cellular therapy programs.

Bellicums CaspaCIDe safety switch may facilitate the use of cell therapies where cytokine release syndrome and neurotoxicities have been observed, in pursuit of novel targets with on-target/off-tumor safety concerns, and in conjunction with next-generation higher potency cell therapy constructs.

We are excited to expand our CaspaCIDe agreement with MD Anderson to include a broader set of programs to benefit cancer patients, said Rick Fair, President and CEO of Bellicum Pharmaceuticals. We believe that our switch technology may enhance the benefit/risk profile of cell therapies. We intend to continue to pursue opportunities to expand its use via external collaborations with other leaders in the field.

Upon exercise of each option typically expected to be upon out-license of an MD Anderson program that incorporates iC9 Bellicum will receive an upfront payment and will be entitled to a percentage of certain consideration paid to MD Anderson by the third party. Bellicum also will receive a single-digit-percent royalty on global sales of the product. Additional details of the financial arrangements are not disclosed. Bellicum and MD Anderson have agreed on the first two programs for development concurrent with the execution of the agreement. This agreement expands upon a previous one, which covers the use of CaspaCIDe in a specific MDAnderson cell therapy program.

The unique inducible caspase-9 technology covered by this agreement has the potential to reduce the risk of serious adverse events associated with cellular therapies and to improve patient outcomes, said Katy Rezvani, M.D., Ph.D., professor of Stem Cell Transplantation and Cellular Therapy atMD Anderson. We have successfully applied the technology to existing cell therapies, and we look forward to the potential future applications made possible by this agreement.

- 30 -

About MD Anderson

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institutions sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 51 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is No. 1 for cancer in U.S. News & World Reports Best Hospitals rankings. It has been named one of the nations top two hospitals for cancer since the rankings began in 1990 and has ranked first 16 times in the last 19 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The companys next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicums GoCAR-Tproduct candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at http://www.bellicum.com.

More:

MD Anderson and Bellicum Announce Additional License Agreement for Use of CaspaCIDe Safety Switch - Newswise

Will the Taliban’s takeover lead to a new refugee crisis from Afghanistan? – Afghanistan – ReliefWeb

By Nasrat Sayed, Fahim Sadat, and Hamayun Khan

The decision to withdraw U.S. and NATO troops from Afghanistan and the subsequent abrupt takeover by the Taliban have triggered profound concerns among Afghans, who fear for the future under the Talibans rule. Internationally, one key concern is that a major refugee crisis may be imminent, which could swell the numbers of Afghans previously displaced within and beyond the countrys borders during prior decades of war. Already this year, more than 558,000 Afghans have been displaced internally. Under a worst-case scenario, an estimated 515,000 refugees could be forced out of the country by the end of this year. Future flight would add to the existing 2.8 million Afghan refugees and asylum seekers around the world, who have long been among the planets largest humanitarian populations.

Afghanistans neighborsparticularly Pakistan and Iran, which already host more than 2.2 million registered Afghan refugees and more than 3 million others with varying statuswould be the most affected by any large-scale migration. However, refugees could also seek refuge in Europe, in a possible echo of the more than 1 million asylum seekers and others from Syria, Afghanistan, Iraq, and elsewhere who reached EU borders in 2015 and 2016. Fearing such a repetition, European policymakers initially pressed for continued returns to Afghanistan of irregular Afghan migrants and failed asylum seekers; however, several countries leading the charge for a stiff returns policy, among them Germany, the Netherlands, and Sweden, quickly reversed course as the Taliban gained ground.

The likelihood of a new Afghan refugee crisis primarily depends on the formation and structure of a government by the Taliban, its rules (such as regarding rights for women and girls to an education and work), and the countrys economic situation. The inability of the Taliban to form an inclusive government that is acceptable to all Afghans may cause turbulence. This, along with continued drought that has compounded the humanitarian situation, may increase the number of people who are willing to flee, especially to neighboring countries where leaders have worried openly about a new refugee crisis. More broadly, global powers have fretted that a fragmented Afghanistan could again play host to extremist groups as it did ahead of the 9/11 terrorist attacks.

However, these outcomes are not inevitable. Taliban leaders have suggested they will behave differently than the last time the group was in power, with more tolerance and respect for women and minority rights. The international communitys ongoing relationship with Afghanistan and Afghan organizations can affect the new governments performance and ability to maintain control. External pressures, particularly from Afghanistans neighbors, may limit civilians ability to flee. Negotiations between the Taliban and opposition forces could lead to an inclusive government. While there remains the prospect that renewed fighting, economic disaster, or reduced freedom will prompt a large-scale refugee crisis, the countries that are most likely to be affected will be those located in Afghanistans immediate neighborhood, many of which have invested diplomatic and other resources to prevent huge displacement.

This article reviews the prospects for a new refugee crisis from Afghanistan following the Talibans takeover. It tracks the history of forced migration from Afghanistan, including in the two decades since the U.S.-led invasion in 2001, and examines the factors that could be crucial in seeding a new refugee crisis.

Four Decades of Refugees

After Syrians and Venezuelans, Afghans already account for the third largest population of forced migrants worldwide. A portion of this migration has been going on for more than four decades, as the country has been engulfed by a series of wars and invasions including by the Soviet Union and, more recently, a U.S.-led coalition.

Historically, Pakistan and Iran have hosted most of these refugees; as of December 2020, Pakistan hosted 1.4 million registered Afghan refugees and Iran hosted 780,000. Many more Afghans live in those countries without registration; estimates suggest that 1 million unregistered Afghans live in Pakistan and more than 2 million Afghans live in Iran in irregular status.

The years between the Soviet Unions invasion in 1979 and the end of the Talibans previous regime in 2001 saw intense refugee movements to Pakistan, Iran, and the West. Initially, both Iran and Pakistan welcomed influxes of Afghan refugees, with financial support from the international community. However, in the 1990s both countries changed their policies and in 1997 stopped registering new Afghan refugees.

These two countries have had different policies in terms of refugees access to education, right to work, and freedom of movement. For example, Pakistan permits freedom of movement for registered Afghans, whereas Iran imposes restrictions. In Pakistan, approximately one-third of refugees lived in refugee villages as of 2018, while the vast majority of Afghan refugees in Iran lived in urban areas. However, both countries have been host to many cases of mistreatment and alleged violations of Afghan refugees human rights, including forced deportation, detention, and physical abuse.

Europe also has been a significant destination for Afghans, dating to the 1980s. Within Europe, Germany hosts the largest number of Afghan nationals (nearly 272,000 as of 2020, according to the German Federal Statistical Office). Turkey has been a typical host and transit country for irregular migration of Afghans to Europe. But since 2002, due to the engagement of the international community in Afghanistan and the 2015-16 refugee crisis, Afghans seeking protection in Europe have seen lower rates of approval for their asylum claimsat times significantly lower than rates for asylum seekers from Syria and other conflict zones.

Uneven Returns

Between 2002 and 2014, during which time Afghanistan saw large numbers of international forces on its soil, refugee movements not only slowed but millions of Afghans returned. Since 2002, nearly 5.3 million refugees have returned to Afghanistan under a program facilitated by the UN High Commissioner for Refugees (UNHCR). However, this programs pace has slowed dramatically. More than 1.8 million refugees returned to the country through this program in 2002, but fewer than 2,150 returned in 2020 (see Figure 1 in the PDF).

Unregistered Afghans in Iran have been returning at a much greater rate. In 2020, more than 859,000 Afghans with irregular status in Iran returned to Afghanistan, according to the International Organization for Migration (IOM)more than ever before. Many of these migrants were deported or forcibly returned by Iranian authorities. In May 2020, the harsh conditions for Iran-bound Afghans attracted international news when 45 migrant workers reportedly drowned in the Harirud River after being forced into the water at gunpoint by Iranian border guards.

Some Afghans have also been forcibly returned from Pakistan, their treatment usually depending on Pakistans political relations with Afghanistan at the time. For example, due to the deteriorating security situation in Pakistan, nearly 365,000 refugees and more than 200,000 irregular migrants were forced to return to Afghanistan in just the second half of 2016, in what Human Rights Watch called the worlds largest unlawful mass forced return of refugees in recent times.

Outside the region, the European Union and Afghanistan signed a Joint Way Forward (JWF) agreement in 2016, with the aim to return failed Afghan asylum seekers. This April, the JWF was replaced with Joint Declaration on Migration Cooperation (JDMC). Nearly 30,000 Afghan citizens were returned from the 27 EU Member States between 2016 and 2020, according to EU statistics. Elsewhere, Turkey has also deported irregular Afghans, including some 6,000 people deported to Afghanistan in 2020.

Returned Afghans often face unemployment and precarious socioeconomic conditions in their native country. This situation has become more extreme in recent weeks, with the economy slowing down drastically following the Talibans resurgence. COVID-19 also remains a perilous issue, having a negative impact on the livelihoods of all Afghans, especially returnees. The pandemic significantly limited returnees access to work, and they have also faced barriers accessing health-care facilities, financial sources, and information on where to obtain basic services.

A New Crisis?

Fears of a new refugee crisis have mounted since February 2020, when the United States signed a peace agreement with the Taliban and pledged to withdraw troops in 2021. President Joe Biden confirmed the U.S. commitment to withdraw troops by September, and the final U.S. forces left the country at the end of August. Ahead of their departure, the Taliban laid claim to large swaths of Afghanistan and, on August 15, took over the capital of Kabul, likely presaging new limitations on civil liberties and a rollback of the countrys embryonic democracy.

In coming months, a few key factors may determine the countrys future and whether many civilians will flee their homes. One will be the nature of the Talibans leadership, and whether it respects human rights or follows a strict interpretation of Sharia law. New leaders also face the task of bringing political and economic stability to their country and preventing the growth of the Islamic State.

A second issue is whether the withdrawal of international troops leads the international community to abandon Afghanistan as a whole and for the long term. Financial aid and other humanitarian assistance could be more crucial than ever in coming months and years. The United States and NATO had previously pledged continuing support to Afghanistan post-withdrawal, but Western powers and multilateral institutions such as the International Monetary Fund (IMF) and the World Bank have frozen the countrys access to money in recent weeks. The Talibans lip service to rights for women and girls and slow formation of a new government may indicate leaders hopes to gain international recognition and avoid diplomatic and financial isolation. Doing so might make possible the flow of international assistance. The European Union, for instance, has said that the billions of dollars it has pledged in development aid depend on conditions such as the Talibans respect for human rights.

Another outstanding question is whether there will be a resumption of full-scale civil war, which would be unlikely to benefit any single group or the country as a whole. The emergence of a group of resistance fighters based in Panjshir province, called the National Resistance Front of Afghanistan, is sure to add a new chapter to the situation, as will tensions with a regional affiliate of the Islamic State that was behind the August attack outside Hamid Karzai International Airport, which killed more than 180 people. Renewed war would imperil the formation of a new Taliban government and could make further remote the opportunity for international organizations to implement developmental projects and provide support for good governance.

If large-scale refugee flows do occur, they would be most likely to affect Pakistan and Iran in the short term, followed by central Asian countries, some of which have previously bristled at hosting Afghan refugees. Under a worst-case scenario, UNHCR estimated that up to 515,000 refugees could cross into these neighboring countries by the end of the year, although the agency had not observed large numbers of border crossings as of late August, perhaps partly due to frequent border closures. In many of these neighboring countries, anxieties about Afghanistans uncertain situation have been exacerbated by the economic fallout due to the COVID-19 pandemic and, for Iran, from ongoing crippling U.S. economic sanctions. Iran and Pakistan also are dealing with significant water scarcity, which may affect their attitudes towards regional stability.

High Obstacles to Reach Europe

At present, the prospects appear slim that a major refugee crisis will spread significantly beyond the region and ultimately to Europe, at least in the near term. One barrier is the high cost that smugglers charge asylum seekers, which averaged U.S. $7,500 in 2015, Afghanistans Ministry of Refugees and Repatriations said at the time. Given the abysmal poverty in Afghanistan, where more than one-third of the population lives below the international poverty line of U.S. $1.90 per day, this cost is far beyond the capacity of most Afghans. Individuals financial situations have been even more constrained since the outbreak of the pandemic.

Additionally, many Afghans are already aware of the dangers of irregular migration and strict border-control measures that have been imposed by several European countries since the 2015-16 period. In 2016, the European Union and Turkey agreed on a deal to prevent irregular migration from Turkey to Greece, involving the return of irregular migrants reaching the Greek islands. The EU-Turkey deal contributed to decreasing numbers of irregular migrants arriving in Europe: there were nearly 862,000 irregular arrivals in Greece in 2015, but fewer than 16,000 in 2020.

Some of these border measures have been bolstered in recent weeks: Turkey, which is already hosting more than 3.6 million Syrian refugees and is a main transit hub for Europe-bound Afghan asylum seekers and other migrants, has started to reinforce its border with Iran with a three-meter high wall, ditches, and barbed wire. Turkish President Recep Tayyip Erdoan has said his country will not be "Europe's refugee warehouse. Greece, meanwhile, has completed a 25-mile (40-kilometer) fence barrier along its border with Turkey. These border measures show that the path to Europe will be difficult for Afghans.

Tough Choices Ahead

Serious talks for a political settlement between the Taliban and resistance forces could avoid a situation in which large numbers of civilians feel the need to flee the country for their own safety. Partners such as the European Union and the United States could contribute to this end by providing economic and humanitarian support to Afghan organizations operating on the ground. The U.S. Treasury Department recently took a step in this direction by allowing humanitarian organizations to provide aid in the country, despite antiterrorism sanctions against the Taliban.

The Talibans ability to gain recognition as a government could hinge on a political settlement with resistance fighters, which might grant it a degree of trust and legitimacy both within and outside the country. Decades of war have shown that peace is not easily won. Both the Taliban and resistance leaders have called for negotiations and an inclusive government; if achieved, this might prove the surest way of bringing peace to the country and allow Afghans to feel safe in their communities.

Finally, Taliban leaders have a crucial role to play in carrying out the duties of governing. Tolerance for human rights, including rights for women and girls, will win it respect internationally and from the Afghan people. Furthermore, corruption has been a serious issue which eroded the previous governments legitimacy in the eyes of the public. Good governance and effective delivery of basic services could therefore instil trust in the new government and reinforce its mandate. This includes the governments attention to former refugees and other returned migrants, whose reintegration will be critical for Afghanistans future. Diplomatic and other efforts that support reforms along these lines would pay dividends.

The views expressed in this article are solely those of the authors and do not reflect their affiliated institutions.

CONTACTSource@MigrationPolicy.org

Sources

Asian Development Bank. 2021. Poverty Data: Afghanistan. Updated April 29, 2021. Available online.

Al Jazeera. 2021. European Countries Halt Deportations amid Afghanistan Fighting. Al Jazeera, August 12, 2021. Available online.

Amnesty International. 2019. Afghanistans Refugees: Forty Years of Dispossession. News release, June 20, 2019. Available online.

Arian, Farhad. 2018. Irans Mistreatment of Afghans: Human Rights Violations of Refugees and Asylum Seekers. Refugee Research Online, January 26, 2018. Available online.

Associated Press. 2021. Erdogan Says Turkey Is Not Europes Refugee Warehouse. Associated Press, August 19, 2021. Available online.

Blinken, Antony J. 2021. Secretary Antony J. Blinken with Jake Tapper of CNNs the Lead with Jake Tapper. Interview transcript, April 27, 2021. Available online.

Brussels International Center. 2019. Iran and Climate Refugees: An Alarming Situation. Brussels: Brussels International Center. Available online.

Dawi, Akmal. 2015. Afghan Emigration to Europe Seen as Setback. Voice of America, December 29, 2015. Available online.

Deutsche Welle. 2017. Hungary Completes Second Fence to Keep Out Migrants. Deutsche Welle, April 28, 2017. Available online.

Dixon, Robyn. 2021. The World Should Unfreeze Afghanistans Reserves and Pour In Aid to Rebuild the Country, Russia Says. Washington Post, August 30, 2021. Available online.

Domnguez, Gabriel. 2015. Little Help for 'Mistreated' Afghans in Pakistan. Deutsche Welle, November 18, 2015. Available online.

Eurostat. 2021. Third Country Nationals Returned Following an Order to Leave Annual Data Rounded. Updated July 12, 2021. Available online.

European Council. 2016. EU-Turkey Statement. Press release, March 18, 2016. Available online.

Federal Statistical Office of Germany. 2021. Migration and Integration: Foreign Population by Sex and Selected Citizenships. Updated March 29, 2021. Available online.

Harris, Chris. 2015. Is Bulgaria's Border Wall Forcing Migrants to Risk Deadly Crossings? EuroNews, April 30, 2015. Available online.

Human Rights Commission of Pakistan. 2019. State of Human Rights in 2018. Lahore: Human Rights Commission of Pakistan. Available online.

Human Rights Watch. 2013. Unwelcome Guests: Irans Violation of Afghan Refugee and Migrant Rights. N.p.: Human Rights Watch. Available online.

International Organization for Migration (IOM). 2020. Return of Undocumented Afghans: Weekly Situation Report, 20-31 December 2020. Kabul: IOM Kabul. Available online.

---. 2020. Return of Undocumented Afghans: Weekly Situation Report, 29 December 2019 4 January 2020. Kabul: IOM Kabul. Available online.

Khan, S. 2021. Is Pakistan Prepared to Deal with Climate Migration? Deutsche Welle, January 4, 2021. Available online.

Kirici, Kemal and Fulya Memisoglu. 2021. Bidens Decision to Pull Troops from Afghanistan Risks a Major Refugee Crisis. Just Security, April 26, 2021. Available online.

Koelbl, Susanne. 2021. Interview with U.S. Special Envoy to Afghanistan: We Will Not Abandon Afghanistan. Der Spiegel, May 10, 2021. Available online.

Pitonak, Amy and Mehmet Enes Beer. 2017. A Neglected Population: Afghan Migrants in Europe. Commentary, Istituto Affari Internazionali, December 13, 2017. Available online.

Mixed Migration Centre (MMC). 2020. Understanding the Impact of COVID-19 on Afghan Returnees. Fact sheet, MMC Asia 4Mi Snapshot, MMC, N.p., May 2020. Available online.

UN Office for the Coordination of Humanitarian Affairs (OCHA). 2021. Afghanistan: Snapshot of Population Movements (January to December 2020). Kabul: OCHA Afghanistan. Available online.

Putz, Catherine. 2021. Taliban Takeover: World Bank and IMF Halt Aid; US Freezes Afghan Assets. The Diplomat, August 26, 2021. Available online.

Sediqi, Abdul Qadir and Storay Karimi. 2020. Exclusive: Afghan Lawmakers Say 45 Migrants Drowned after Iranian Guards Forced Them into River. Reuters, May 7, 2020. Available online.

Seir, Ahmad, Rahim Faiez, Kathy Gannon, and Joseph Krauss. 2021. Taliban Vow to Respect Women, Despite History of Oppression. Associated Press, August 17, 2021. Available online.

Simpson, Gerry. 2017. Pakistan Coercion, UN Complicity: The Mass Forced Return of Afghan Refugees. New York: Human Rights Watch. Available online.

Talley, Ian and Mengqi Sun. 2021. Humanitarian Efforts in Afghanistan Get OK From Treasury, Bypassing Sanctions on Taliban. Wall Street Journal, August 26, 2021. Available online.

Tagaris, Karolina. 2021. Greece Completes Border Wall Extension to Deter Potential Afghan Migrants. Reuters, August 21, 2021. Available online.

Terry, Kyilah. 2021. The EU-Turkey Deal, Five Years On: A Frayed and Controversial but Enduring Blueprint. Migration Information Source, April 8, 2021. Available online.

TOLOnews. 2021. Stoltenberg Outlines NATOs Future Support to Afghanistan. TOLOnews, May 21, 2021. Available online.

UN High Commissioner for Refugees (UNHCR). 2020. UNHCR. Registered Afghan Refugees in Pakistan. Available online.

---. 2021. Afghanistan Situation External Update - 20 August 2021. Bangkok: UNHCR Regional Bureau for Asia and the Pacific. Available online.

---. 2021. Afghanistan Situation: Regional Refugee Preparedness and Response Plan. Bangkok: UNHCR Regional Bureau for Asia and the Pacific. Available online.

---. 2021. Global Trends: Forced Displacement in 2020. Copenhagen: UNHCR Global Data Service. Available online.

---. 2021. Onward Movements of Afghan Refugees. Fact sheet, UNHCR Regional Bureau for Asia and the Pacific, Bangkok, March-April 2021. Available online.

---. 2021. Operational Data Portal: Afghanistan Situation. Updated August 23, 2021. Available online.

---. 2021. Operational Data Portal: Mediterranean Situation - Greece. Updated July 11, 2021. Available online.

---. 2021. Refugee Data Finder. Updated June 18, 2021. Available online.

---. N.d. Refugees in Iran. Available online.

Worden, Scott, Johnny Walsh, Belquis Ahmadi, and Richard Olson. 2021. U.S. Withdrawal from Afghanistan: End to an Endless War? Commentary, United States Institute of Peace, April 15, 2021. Available online.

Willner-Reid, Matthew. 2017. Afghanistan: Displacement Challenges in a Country on the Move. Migration Information Source, November 16, 2017. Available online.

World Bank Group. 2020. Supporting Inclusive Growth in Afghanistan. World Bank Group, November 4, 2020. Available online.

Zetter, Roger. 2018. Protection for Forcibly Displaced Afghan Populations in Pakistan and Iran. Copenhagen: Danish Refugee Council. Available online.

Original post:

Will the Taliban's takeover lead to a new refugee crisis from Afghanistan? - Afghanistan - ReliefWeb

The Post goes on patrol with feds to witness Biden’s border crisis first hand – New York Post

SUNLAND PARK, NM The plastic rosary was already falling apart, its white beads spilling onto the wet ground when the young woman was picked up by Border Patrol agents in predawn darkness.

The migrant from Guatemala, who had just run across patches of scrubland between Mexico and the US, refused to give her name. She was handed a plastic bag to stow her few belongings hoop earrings, a creased card with an image of the Virgin Mary. She was told to remove the laces from her mud-caked sneakers. Laces and belts can be used as weapons, or to commit suicide, and Border Patrol agents demand they be removed as soon as people are caught.

Asked if she had traveled by herself to the border, the slight young woman who appeared to be in her 20s replied boldly: I am not alone. God is with me.

But she was actually among dozens of migrants apprehended that morning as The Post accompanied a group of Border Patrol agents during a raid Wednesday along the New Mexico and Texas lines near El Paso. The area is one of the busiest crossing points for migrants along the nearly 2,000-mile southern border with Mexico. Migrants in the area cross a mountain range, desert and scrubland to reach the US.

Since the Biden administration eased restrictions at the border earlier this year, federal agents have seen a surge of illegal immigrants attempting to cross, with dramatic increases in single adults, unaccompanied children and members of transnational criminal organizations.

Shortly after President Biden took office in 2021, he rolled back strict immigration policies instituted by his predecessor, including a remain in Mexico mandate which resulted in thousands of non-Mexican migrants waiting in Mexico for immigration hearings in the US. Thousands of migrants poured across the border in the early days of the Biden administration, spurred by promises made by smugglers that they would be more welcome under the new regime, immigration experts said.

In March Biden put Vice President Kamala Harris in charge of the border crisis, and delivered the belated message: Dont come over. After a brief visit to Guatemala to discuss root causes and an even shorter stop at the borderin June, Harris has barely talked about it and nothing has changed. Crossings are still as high as ever.

Its the crisis that Biden is either ignoring or doesnt care that its happening.Agents working in the El Paso Sector have so far detained 155,892 people in fiscal year 2021, which ends on Sept. 30 almost triple the 54,396 in all of FY 2020.

Nearly 80 percent of those making the crossing are single adults, a significant change in the demographics over the last few years that saw more families crossing the border and giving themselves up to Border Patrol agents. In the past, many claimed they were fleeing gang violence in Central America and seeking asylum protection in the US.

Now most migrants are coming to flee COVID and dire economic conditions in their own country, authorities said. They try to evade capture, sometimes attacking the agents who try to apprehend them, Border Patrol agents told The Post. In the past year, attacks against agents have nearly doubled from 23 last fiscal year to to 40 so far this year in the El Paso Sector alone.

Because it is mostly single adults, we are dealing with more criminal activity, said Gloria Chavez, chief patrol agent of the El Paso Sector, which encompasses 125,000 square miles and employs 2,400 agents. We have a mixture of bad actors with the regular migrants.

In the past year, Chavezs agents have seen an increase in stash houses where smugglers and drug traffickers hold kidnapped migrants and often try to extort their families in the US for cash to release them. Agents have busted 270 stash houses this year and also seized 5,936 pounds of marijuana, 683 pounds of methamphetamine, and 336 pounds of cocaine, she said. Forty-four pounds of deadly fentanyl and 37 pounds of heroin were also seized, she said.

Among the scores of migrants entering the country are terrorists who are linked to Mexican drug cartels, agents said. A group of Republican lawmakers who visited the El Paso Sector in March told reporters that some people caught crossing the border were on a US terrorism watch list. Earlier this year, the Customs and Border Protection Agency confirmed to Congress that four people were detained whose names matched those on the FBIs Terrorist Screening database, according to a report. The suspected terrorists three Yemenis and a Serbian national were caught in the El Paso region. Names were not released.

The surge in crossings also includes a spike in unaccompanied children. So far this fiscal year, there have been 18,765 unaccompanied minors compared to 4,832 last year in the El Paso Sector. If the children are Mexican, they are immediately handed over to the Mexican authorities. Minors 17 and under from other countries cannot be immediately deported and are placed in the care of the Department of Health and Human Services Refugee Resettlement and housed in temporary federal shelters until case workers can determine if they have family in the US. About 2,000 children are being temporarily housed at Fort Bliss in El Paso.

HHS conducts an investigation and reaches out to family members or finds a foster family, as in the case of the toddler sisters from Ecuador who were caught on video being dropped over a stretch of border fence in the El Paso Sector in March. The children, aged 3 and 5, were reunited with their parents in New York City in April.

El Paso agents say they are still haunted by the images on an infrared video of the little girls being dropped over the wall in the dark by human traffickers.

There are railroad tracks, rattlesnakes, coyotes and even mountain lions around here, said Joel Freeland, a Border Patrol agent and father of two young girls. They just abandoned those two little girls, and didnt care if they survived.

Ecuadorians who must travel a month by foot and bus over 3,000 miles to reach the US border for the first time in memory now outnumber Mexicans as the most prolific illegalmigrants at the southern frontier, agents said.

Increasingly, agents find themselves involved in rescue work as human smugglers abandon their charges at the border, often lying to them about the distance they have to travel to cross into America. They tell them that they are at the border and have a few paces to walk, meanwhile its like 100 degrees and the border is a lot farther than they have been told, Freeland told The Post.

There have been 31 deaths in fiscal 2021 compared to 10 in 2020 in the El Paso Sector, and Border Patrol agents have been involved in 615 rescues of migrants in distress from extreme heat in the summer and drownings as increased rainfall has swelled the levels of the Rio Grande and nearby canals. Some have also suffered broken bones from hoisting themselves over a border fence that rises between 14 and 30 feet in places, agents said.

You are in danger of dying if you do not summon help, reads a rescue beacon in Spanish and English, one of several in the El Paso sector where migrants can press a button to summon help from agents on patrol.

Migrants caught on the border are returned to Mexico often on the same day they are caught under Title 42, a provision that allows authorities to expel them if they are suspected of carrying a communicable disease. The program began in March 2020 during the height of the COVID pandemic, and has been extended under the current administration.

Many of the migrants interviewed by The Post knew that they would be expelled from the country as soon as the Border Patrol recorded their information. The Post witnessed dozens of migrants walking through metal cages on their way to the Paso del Norte International Bridge that connects El Paso to Ciudad Juarez in Mexico.

Leonardo Velasquez Centeno, 25, had already tried to cross the border several times and knew what fate awaited him.

Under a light drizzle just before dawn on a rubbish-strewn stretch of road, he told The Post he was escaping poverty in Honduras. Even though he had been robbed of most of his $800 cash by Mexican authorities in the southern state of Chiapas, he was determined not to return to a grim future in Honduras.

Whatever they do, I will come back, and I wont stop trying until I get in, he said.

See more here:

The Post goes on patrol with feds to witness Biden's border crisis first hand - New York Post

What the world can do to solve the Afghan refugee crisis – The European Sting

Children running to take cover as the heavy dust and the wind pierce through the Nawabad Farabi-ha IDP camp. UNHCR/Edris Lutfi

This article is brought to you thanks to the collaboration ofThe European Stingwith theWorld Economic Forum.

Author: Khalid Koser, Executive Director, Global Community Engagement and Resilience Fund (GCERF) & Keire Murphy, Junior Associate, Global Community Engagement and Resilience Fund (GCERF)

The evacuation of foreign citizens and Afghan allies from Kabul has been done under a tight deadline and the risk of terrorist attacks. Since August 14, 2021, about 120,000 people have been evacuated by countries around the world.

But thousands remain, mostly local Afghan staff, journalists, and human right activists.

The situation still poses serious challenges. The foreign nationals returning to their countries will have to deal with the trauma that surrounded the evacuations, those who could not get out in time need alternative exit plans, and Afghans who are being hosted in countries like Qatar will have to be permanently resettled.

Nevertheless, it would be a mistake to allow the relative success of the evacuation to distract attention from the far greater demands of displaced and mobile Afghans.

One group is internally displaced persons (IDPs). These are people displaced within their own country. It is estimated that about 250,000 Afghans have fled their homes since the beginning of May, bringing the total number of IDPs in the country to about 3.5 million the third-highest worldwide.

In addition to seeking commitments that the new Afghan leaders will not provide haven to international terrorists, the international community will need to work with the Taliban to manage the IDP crisis.

IDPs represent the most pressing humanitarian emergency in Afghanistan today and meaningful solutions to address the situation should be high on the agenda. This is important because large numbers of IDPs can undermine security, economic growth, and social cohesion.

If the initial promises of the Taliban to respect womens rights and allow political pluralism and dissent are to be believed, we are unlikely to witness a mass exodus of Afghan refugees.

This may also be the case because many Afghans who would be at particular risk of persecution by the Taliban especially the Hazara minority had already fled in the 1990s, during the Talibans previous regime.

This doesnt mean that the Hazara who are still in Afghanistan are not at risk. In fact, Amnesty International recently released a report detailing the Talibans brutal massacre of Hazara men in July 2021.

More prosaically, when it comes to displaced Afghans, Afghanistans neighbours may not allow them in.

But at the same time, many of Afghanistans borders are difficult to police. This means that movement of refugees is possible. Indeed, millions of those who fled the Taliban in the 1990s returned to Afghanistan during the years that US troops were on the ground. In 2020, more than 800,000 returned from Iran alone. These populations are now at risk of being displaced again, in particular considering recent reports of renewed persecution, including executions, of Hazara in areas controlled by the Taliban.

Preparations for a new wave of refugees have already begun. The US has set aside $500 million for urgent refugee needs, and nearly 100 countries have pledged to accept refugees.

These are positive developments, but does not mean that the wave of anti-migrant sentiment has reversed.

For example, Turkey has stepped up construction of a border wall with Iran to keep Afghans out; and the European Union (EU) and many of its member states want to avoid a repeat of the 2015 migrant crisis where more than a million migrants and refugees crossed into Europe, leaving countries struggling to cope with the influx, and creating division in the EU over how best to deal with resettling people.

It becomes clear, therefore, that greater political pressure needs to be brought to bear on the Taliban to allow refugees to cross borders, on neighbouring countries to admit them, and on other countries to host them. The solutions to the current crisis must be of a more permanent nature if the dignity and rights of fleeing Afghans are to be protected.

Neighbouring Iran and Pakistan have adopted a hard line against hosting Afghan refugees because they already host 3.5 million and 1.5 million Afghans respectively. Many of the refugees were fleeing the Soviet invasion of 1979 and then the first Taliban regime in the 1990s.

Because durable solutions like integration, resettlement, and repatriation have not been deployed effectively, some of them have been hosted as refugees in both Iran and Pakistan for over 40 years. With new refugees arriving, there is need to rethink approaches to displaced populations.

The favoured solution for refugees is repatriation. Before the current crisis, Iran, Pakistan, and the EU wanted Afghan refugees to be repatriated to Afghanistan. But considering the situation at hand, it is now important to secure a guarantee that Afghan refugees will not be forcibly returned to their country. The international community must also accept that voluntary repatriation is unlikely to occur at any scale for the foreseeable future.

With more than 132 million people worldwide requiring humanitarian assistance, humanitarian responses must become more efficient and effective at delivering aid to those who need it most.

Cash assistance has been recognized as a faster and more effective form of humanitarian aid compared to in-kind assistance such as food, clothing or education. Cash transfers give more control to their beneficiaries, allowing them to prioritize their own needs. They also have a proven track record of fostering entrepreneurialism and boosting local economies.

When the UN Secretary-General issued a call for innovative ways to improve cash-based humanitarian assistance, the World Economic Forum responded by bringing together 18 organizations to create guidelines for public-private cooperation on humanitarian cash transfers.

The guidelines are outlined in the Principles on Public-Private Cooperation in Humanitarian Payments and show how the public and private sectors can work together to deliver digital cash payments quickly and securely to crisis-affected populations. Since its publication in 2016, the report has served as a valuable resource for organizations, humanitarian agencies and government leaders seeking to increase the effectiveness of humanitarian aid and advance financial inclusion.

Learn more about this project and find out how you can join the Forum to get involved in initiatives that are helping millions of lives every day.

An alternative is to resettle refugees permanently in richer countries. Canada has pledged to resettle 20,000 new Afghan refugees, while Australia will resettle 3,000. But these are spots in their existing resettlement quotas meaning that Afghans will take the place of refugees from other countries. The UK plans to resettle up to 20,000 Afghans in the long term, including those it has already evacuated. While all this is laudable, resettlement numbers are likely to remain low.

Another solution is integration, that is, providing a pathway to citizenship for refugees. Iran and Pakistan have historically resisted this option and are likely to continue to do so. But they should be urged, at the very least, to grant specific rights to refugees, including the right to work. This would reduce the impact of displacement on host communities and governments.

The Afghans who are in the most precarious position are asylum seekers who have not yet been granted refugee status, rejected asylum seekers who have been denied refugee status, and undocumented migrants who are not just in neighbouring countries, but also in Turkey and Europe.

As recently as August 2021, six European countries signed a letter encouraging fleeing Afghans to return home, despite the Taliban gaining ground and pleas from the Afghan government to halt returns because of growing insecurity.

Some of the countries have since backed down, but there is still political pressure for the return of Afghan asylum seekers to their country. This is partly due to the fact that Afghanistan is one of the top three countries of origin for asylum seekers in Europe and has been for the past few years.

There are an estimated 150,000 Afghan Americans, 85,000 Afghan Canadians, and 50,000 Afghan Australians who need to exert pressure on their governments to protect IDPs and refugees, respect international law, and unlock durable solutions.

If the international community is as serious about the wider consequences of recent developments in Afghanistan as it has been about evacuating citizens and allies, then the hard work really begins now.

More:

What the world can do to solve the Afghan refugee crisis - The European Sting